(BPT) - Sponsored by Alkermes
In the midst of a global pandemic, Ashley and Kim, a Texas-based mother-daughter duo working together to treat Kimâs schizophrenia, have seen one surprising emotion rise to the surface: pride.
âSheâs had some down days, but honestly Iâm really proud of her. Sheâs handling the pandemic the best she can,â said Ashley, a caregiver for her mother Kim, who was diagnosed with schizophrenia when she was 30 years old.
While experts say that mental health challenges have become more widespread during the COVID-19 pandemic,
1 Ashley has seen some positive changes in her mother who lives with schizophrenia.
Share:
First and Only FDA Approved Transdermal System Now Available to Nearly 220 Million Insured Adults Living with Schizophrenia in the U.S.
Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced publication of the results from a pivotal, phase 3 trial, which showed that SECUADO
® (asenapine) transdermal system demonstrated significant improvement in Positive and Negative Syndrome Scale (PANSS) total score at Week 6 versus placebo in adult patients with schizophrenia. SECUADO is the first-and-only transdermal patch formulation for the treatment of adults with schizophrenia approved by the U.S. Food and Drug Administration.
1 The data are published in the January/February 2021 edition of the